Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia (Q43627664)

25 November 2017

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia (English)

1 reference

25 November 2017

1 reference

1

1 reference

25 November 2017

2

1 reference

25 November 2017

6

1 reference

25 November 2017

H M Kantarjian

3

1 reference

25 November 2017

P D le Coutre

4

1 reference

25 November 2017

M Baccarani

5

1 reference

25 November 2017

D W Kim

7

1 reference

25 November 2017

X Fan

8

1 reference

25 November 2017

S Novick

9

1 reference

25 November 2017

F J Giles

10

1 reference

25 November 2017

9 November 2012

1 reference

25 November 2017

1 reference

25 November 2017

27

1 reference

25 November 2017

1411-1413

1 reference

25 November 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.324

25 November 2017

0 references

cites work

Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.324

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.324

1 reference

Dimensions Publication ID

25 November 2017

1009983411

0 references

Fatcat ID

release_hvpljdmijvej7jtrt3d6lk2zwy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hvpljdmijvej7jtrt3d6lk2zwy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference